The DMTA cycle depends on clear data flow, yet most labs still work across disconnected systems. Sean McGee, Director of ...
In the pharmaceutical discovery process, understanding a drug’s residence time—the duration a molecule remains bound to its ...
In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and ...
Explore how AI-driven multiomics is reshaping drug discovery and personalized medicine development through innovative data ...
Discover how AI is revolutionizing RNA drug development in a new article published in Engineering. Learn about the potential ...
News-Medical.Net on MSN
Artificial intelligence unlocks new frontiers in RNA drug design
In the realm of modern medicine, RNA-based therapies have emerged as a promising avenue, with significant advancements in metabolic diseases, oncology, and preventive vaccines. A recent article ...
Multi-year partnership with France's Servier will use Insilico's AI platform to explore novel cancer drugs Newly Hong ...
This article is based on a poster originally authored by Daniel A. Barr, Mario Öeren, Peter A. Hunt, Jonathan D. Tyzack, Tomáš Chrien, Tamsin E. Mansley and Matthew D. Segall, which was presented at ...
Matthias Trost (left) is a Professor at Newcastle University (UK) with a lab comprising three focuses: method development for proteomics, the application of mass spectrometry in drug discovery and the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback